Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naïve pulmonary hypertension

Jose, Arun; Kher, Akhil; O’Donnell, Rachel; Elwing, Jean M.

doi:10.1016/j.ejrad.2019.108784

Cited by 5 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…( 32 ), 2020 U.K. PCS NR 30 80 47 ± 5 NR 30 24 (17–24) 8 (26) Jose et al. ( 30 ), 2020 ∗ U.S. RCS 2013–2019 38 68 51 ± 17 45 ± 15 18 20 20 (11–35) 4 (11) Kang et al. ( 19 ), 2013 South Korea PCS 2009–2010 30 74 45 ± 13 51 ± 23 19 2 7 2 17 ± 7 1 (3) 6 (20) Knight et al.…”

Section: Resultsmentioning

confidence: 99%

“…Our comprehensive search identified a total of 22 studies that were included in the meta-analysis ( 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ). The details of the literature search are presented in the supplemental materials, including a Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow diagram ( Supplemental Appendix 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…IPAH comprised 51% and CTD-PAH 26% of the PAH population. Dawes 2018 ( 31 ), de Siqueira 2016 ( 16 ), and Jose 2019 ( 30 ) kindly provided additional data that allowed identification of patients with PAH from a mixed PH cohort.…”

Section: Resultsmentioning

confidence: 99%

“…The authors are very grateful for the support and collaboration of the following people who kindly provided unpublished data: Dr. Nobuya Abe and Dr. Masaru Kato (Abe 2019 [ 12 ]), Professor Roberto Badagliacca and Professor Carmine Dario Vizza (Badagliacca 2016 [ 13 ]), Dr. Melanie Brewis (Brewis 2018 [ 15 ]), Dr. Ellen Ostenfeld (Bredfelt 2018 [ 14 ]), Dr. Tim Dawes and Dr. Declan O’Regan (Dawes 2018 [ 31 ]), Dr. Maria Eduarda Menezes de Siqueira and Professor Adriano Mendes Caixeta (de Siqueira 2016 [ 16 ]), Dr. Dan Knight and Professor Vivek Muthurangu (Knight 2016 [ 20 ]), Dr. Liam Zhong (Leng 2019 [ 21 ]), Dr. Sophia Mouratoglou and Dr. George Giannakoulas (Mouratoglou 2018 [ 23 ]), Dr. Arun Jose and Dr. Jean Elwing (Jose 2019 [ 30 ]), Dr. Catherine Simpson and Professor Paul Hassoun (Simpson 2019 [ 25 ]), Dr. Andy Swift (Swift 2017 [ 26 ]) and Dr. Mariëlle van de Veerdonk and Professor Anton Vonk Noordegraaf (Van de Veerdonk 2011 [ 27 ]). The authors also thank Dr. Maria Sukhanenko for her help with extracting data from a Russian study.…”

Section: Acknowledgmentsmentioning

confidence: 99%

See 3 more Smart Citations

Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

Alabed¹,

Shahin²,

Garg

et al. 2021

JACC: Cardiovascular Imaging

View full text Add to dashboard Cite

Objectives This meta-analysis evaluates assessment of pulmonary arterial hypertension (PAH), with a focus on clinical worsening and mortality. Background Cardiac magnetic resonance (CMR) has prognostic value in the assessment of patients with PAH. However, there are limited data on the prediction of clinical worsening, an important composite endpoint used in PAH therapy trials. Methods The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Web of Science databases were searched in May 2020. All CMR studies assessing clinical worsening and the prognosis of patients with PAH were included. Pooled hazard ratios of univariate regression analyses for CMR measurements, for prediction of clinical worsening and mortality, were calculated. Results Twenty-two studies with 1,938 participants were included in the meta-analysis. There were 18 clinical worsening events and 8 deaths per 100 patient-years. The pooled hazard ratios show that every 1% decrease in right ventricular (RV) ejection fraction is associated with a 4.9% increase in the risk of clinical worsening over 22 months of follow-up and a 2.2% increase in the risk of death over 54 months. For every 1 ml/m 2 increase in RV end-systolic volume index or RV end-diastolic volume index, the risk of clinical worsening increases by 1.3% and 0.7%, respectively, and the risk of mortality increases by 0.9% and 1%. Every 1 ml/m 2 decrease in left ventricular end-systolic volume index or left ventricular end-diastolic volume index increased the risk of death by 2.1% and 2.3%. Left ventricular parameters were not associated with clinical worsening. Conclusions This review confirms CMR as a powerful prognostic marker in PAH in a large cohort of patients. In addition to confirming previous observations that RV function and RV and left ventricular volumes predict mortality, RV function and volumes also predict clinical worsening. This study provides a strong rationale for considering CMR as a clinically relevant endpoint for trials of PAH therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Acknowledgmentsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

Alabed¹,

Shahin²,

Garg

et al. 2021

JACC: Cardiovascular Imaging

View full text Add to dashboard Cite

show abstract

“…Sie sind möglicherweise besser für die Planung einer pulmonalen Ballonangioplastie geeignet, da sie eine höhere Auflösung als die konventionelle Bildgebung bieten [60]; kleine Lungengefäße lassen sich manchmal besser als in der Pulmonalisangiografie beurteilen [59]. [74,75].…”

Section: Computertomografie Des Thoraxunclassified

Aktuelle Definition und Diagnostik der pulmonalen Hypertonie

et al. 2020

View full text Add to dashboard Cite

ZusammenfassungDie 6. Weltkonferenz für pulmonale Hypertonie (PH) fand vom 27. 2. – 1. 3. 2018 in Nizza statt. Hier wurden die Erkenntnisse auf dem Gebiet der PH der letzten 5 Jahre nach Aufarbeitung und Diskussion über einen längeren Vorbereitungszeitraum von 13 Arbeitsgruppen präsentiert und in der Folge zum Jahreswechsel 2018/2019 publiziert. Einer der seither intensiv diskutierten Vorschläge ist der einer Änderung der hämodynamischen Definition der PH mit Absenkung des Grenzwertes für den mittleren pulmonalarteriellen Druck von ≥ 25 auf > 20 mmHg, gemessen im Rechtsherzkatheter in Ruhe. Zusätzlich wurde der pulmonalvaskuläre Widerstand in die PH-Definition aufgenommen, was die Wichtigkeit der Bestimmung des Herzzeitvolumens während der Rechtsherzkatheteruntersuchung unterstreicht.Die Rationale sowie mögliche Auswirkungen der neuen PH-Definition, zu welchen zwischenzeitlich bereits neue Publikationen erschienen sind, möchten wir in diesem Übersichtsartikel diskutieren. Ferner ist ein aktueller Überblick zur nicht-invasiven und invasiven Diagnostik der PH enthalten, in welchem auf den Stellenwert der Methoden für Diagnostik, Differenzialdiagnostik und Prognose sowie weitere Neuerungen der 6. PH-Weltkonferenz eingegangen wird. Ergänzt haben wir einen Abschnitt zum Stellenwert von Belastungsuntersuchungen für das Erkennen und die Verlaufsbeurteilung der PH, welche bei der Diskussion in Nizza und in den nachfolgenden Publikationen zumindest erwähnt, aber nicht ausführlicher besprochen wurden.

show abstract

The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Cardiac magnetic resonance imaging as a prognostic biomarker in treatment-naïve pulmonary hypertension

Cited by 5 publications

References 36 publications

Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

Aktuelle Definition und Diagnostik der pulmonalen Hypertonie

The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension

Contact Info

Product

Resources

About